Document is current
Any future updates will be listed below
-
Authors
Tegethoff, Paulina https://orcid.org/0000-0002-4701-4309
Perneczky, Robert https://orcid.org/0000-0003-1981-7435
Hufnagel, Anna
Kehrls, Manolo
Wüsten, Nikola Clara-Sophie
Kurz, Carolin https://orcid.org/0000-0003-4299-6240
-
Funding
Funding for this research was provided by:
Klinikum der Universität München
- License Information
-
More Information
Article History
Accepted: 5 September 2024
First Online: 18 September 2024
Declarations
:
: Participants were recruited from the CogScreen study (project number 22–0786), a cohort study investigating the feasibility of screening for Alzheimer’s disease (AD) in the general population, which started in 02/23. A comparison group was recruited from the SCD-Q study (project number 22-1117) at the Memory Clinic of the Department of Psychiatry and Psychotherapy, University Hospital Munich, LMU Munich, which started in 04/23. Both studies were approved by the local ethics committee of the Ludwig-Maximilians-University Munich (project numbers 22–0786 and 22-1117). Permission to reproduce material from other sources is not required as proprietary data is used for this manuscript. CogScreen has been retrospectively registered at clinical trials (NCT06191952).
: All authors ensure that informed consent was appropriately obtained, that the research met ethical guidelines, including compliance with the legal requirements of the country of the study. Written informed consent was obtained from all participants in accordance with the 1964 Declaration of Helsinki.
: The authors report no conflicts of interest for the studies presented. R.P. competing interests are described in the acknowledgements. R.P. has received honoraria for advisory boards and speaker engagements from Roche, EISAI, Eli Lilly, Biogen, Janssen-Cilag, Astra Zeneca, Schwabe, Grifols, Novo Nordisk and Tabuk.
